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 Abstract   
Objectives: To determine the effects of tamoxifen and hormone replacement therapy in order to assess their role 
in depressive behavior.
Material and Methods: Different protocols of hormone replacement therapies were administered to surgically 
ovariectomized rats. Intact rats were used for tamoxifen experiments. Properly assigned control groups were used 
and cognitive processes were studied on animal models of surgical menopause using the Porsolt Forced Swim Test 
and locomotor activity experiments.
Results: In the tamoxifen experiments, an interaction between treatment and days did not reach statistical 
significance, but indicated a trend in this direction [F(1,26)=3.557, p=0.071]. The number of repeated movements 
significantly decreased after the Porsolt test (F(1,44) = 8.483, P<0.006) in the hormone replacement experiments. 
In the tamoxifen experiments, the number of repeated movements significantly decreased after the Porsolt test 
(F(1,26) = 74.410, P<0.001).
Conclusions: While sequential hormone replacement is found to be protective against depression, tamoxifen 
seems to augment behavioral despair.
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Introduction
In	 the	 postmenopausal	 period	 many	 body	 systems	 are	
affected	by	reduced	estrogen	levels	and	have	a	negative	impact	
on	 the	 quality	 of	 life.	 Cognitive	 defects	 and	 mood	 disorders,	
including	a	spectrum	of	symptoms	from	mild	mood	changes	to	
severe,	major	depression,	are	among	these	problems.	Because	the	
lifetime	prevalence	of	depression	in	women	is	twice	as	high	as	in	
men,	gonadal	hormones	may	play	a	role	in	this	gender	disparity	
[1].
Experimental	and	clinical	 studies	provide	evidence	 for	 the	
antidepressant	and	cognitive	effects	of	estrogens	[2-7].	An	increase	
in	sensory	perception,	decreased	seizure	threshold,	reduced	acute	
phase	 inflammatory	response,	 increased	 in	cerebral	blood	flow,	
augmented	 cerebral	 blood	 glucose	 utilization,	 enhanced	 mood	
effects,	 and	 reduced	 formation	 of	 β-amyloid	 have	 been	 shown	
[8].
Selective	 estrogen	 receptor	 modulators	 (SERMs)	 are	
synthetic,	 non-hormonal	 compounds	 acting	 as	 estrogen	
agonists	on	tissues	such	as	bone	and	brain,	while	functioning	as	
estrogen	 antagonists	 on	 other	 tissues,	 including	 the	 breast	 and	
the	 uterus	 [9,	 10].	 Recent	 studies	 [11,	 12],	 as	 well	 as	 a	 study	
conducted	in	our	department	[13],	have	indicated	that	raloxifene	
has	 a	 neuroprotective	 effect	 on	 the	 central	 nervous	 system.	
Tamoxifen	is	used	as	an	adjuvant	therapy	for	breast	cancer	and	
there	are	studies	on	clinical	cognitive	effects	on	postmenopausal	
women	[14,	15],	but	there	is	very	limited	data	about	the	effect	of	
tamoxifen	on	mood	disorders.		
 
Objectives
The	 objective	 of	 the	 present	 study	 was	 to	 determine	 the	
effects	 of	 tamoxifen	 and	 hormone	 replacement	 therapy	 with	
different	 hormone	 regimens	 to	 assess	 their	 role	 in	 depressive	
behavior.
Material and methods
Experimental Animals.	 Adult	 sexually	 mature	 female	
Sprague	Dawley	rats	(190-250	g)	were	used	for	the	experiments.	
Rats	were	housed	(3–4	rats/cage)	in	standard	plastic	cages	with	
food	and	water	provided	ad libitum	during	the	habituation	period	
for	2	weeks.	Animals	were	maintained	on	12:12	h	light-dark	cycle	
(lights	on	07:00–19:00).	Manipulations	of	the	rats	were	performed	
under	the	rules	of	the	Institutional	Animal	Ethics	Committee	of	
Ege	University	(Izmir,	Turkey),	in	compliance	with	the	European	
Communities	Council	Directive	 (2003/003)	 and	 guided	 by	 the	
‘International	 Guiding	 Principles	 for	 Biomedical	 Research	
Involving	Animals’	 developed	by	 the	Council	 for	 International	
Organizations	of	Medical	Sciences	(NIH).	All	the	animals	were	
handled	before	the	tests.
Surgical procedure:	 Postmenopausal	 status	 was	 achieved	
by	 bilateral	 surgical	 ovariectomy.	 Rats	 were	 anaesthetized	 by	
thiopental	 sodium	 (Pentotal;	 40mg/kg,	 intraperitoneal).	 The	
ovaries	were	exteriorized	through	small	bilateral	flank	incisions	
(1	cm	each),	 the	 junctions	between	 the	 fallopian	 tubes	and	 the	
ovaries	were	 ligated,	 the	sides	of	 the	ovaries	were	cut,	and	 the	
ovaries	were	removed.	The	horns	were	returned	to	the	abdominal	
cavity	 through	the	openings	and	 the	skin	 incisions	were	closed	
with	 sutures.	During	 the	 recovery	period	 (1	week)	 the	animals	
were	 housed	 singly	 in	 the	 cages.	 Following	 recovery	 from	 the	
surgery,	 the	 rats	 were	 kept	 under	 standard	 colony	 conditions.	
After	 21	 days	 the	 rats	 were	 randomly	 allocated	 to	 study	 and	
control	groups.	
Hormone/Drugs.	 All	 hormone/drug	 treatments	 were	
applied	for	12	days	intraperitoneally	at	the	same	time	each	day.	
Tamoxifen	(5	mg/kg;	Sigma,	St.	Louis,	MO,	USA)	was	dissolved	
in	10%	DMSO.	The	vehicle	(10%	DMSO)	was	used	for	control	
injections.	Medroxyprogesterone	(2.5	mg/kg)	and	17-β	estradiol	
(50	mg/kg)	were	dissolved	in	sesame	oil.	Progesterone,	tamoxifen,	
and	 sesame	 oil	 injections	 were	 done	 at	 08:30-09:00.	 Estrogen	
injections	were	done	at	16:00-17:00.	The	rat	menstrual	cycle	is	
4	days	and	for	the	sequential	hormone	replacement	progesterone	
injections	were	not	done	for	2	days.	Drug	treatment	was	continued	
for	additional	4	days	in	the	Porsolt	Forced	Swim	Test	(FST)	and	
spontaneous	locomotor	activity	(total,	18	days).
 Streszczenie   
Cel: Określenie wpływu tamoxifenu oraz hormonalnej terapii zastępczej celem oceny ich roli w zachowaniach 
depresyjnych.
Materiał i metody: Różne protokoły hormonalnej terapii zastępczej zastosowano u szczurów poddanych 
chirurgicznemu usunięciu jajników. Tamoxifen podawano szczurom, których nie operowano. Wykorzystano 
odpowiednio dobraną grupę kontrolną. Zbadano procesy poznawcze na modelach zwierzęcych z chirurgiczną 
menopauzą przy pomocy testu Porsolt Forced Swim oraz doświadczeń aktywności ruchowej.
Wyniki: W doświadczeniach z tamoxifenem, związek pomiędzy terapią a dniami nie osiągnął statystycznej istotności, 
ale wykazał trend w tym kierunku [F(1,26)=3,557,p=0,071]. Liczba powtórzeń ruchów istotnie zmniejszyła się po 
teście Porsolta [F(1,44)=8,483,p<0,006] w doświadczeniach z hormonalną terapią zastępczą. W grupie leczonej 
tamoxifenem liczba powtórzeń ruchów istotnie zmniejszyła się po teście Porsolta [F(1,26)=74,410, p<0,001].
Wnioski: Wydaje się, że sekwencyjna terapia hormonalna pełni ochronną funkcję przed depresją, natomiast 
tamoxifen nasila zachowania depresyjne.
 Słowa kluczowe:  tamoxifen / hormonalna terapia zastępcza / depresja / menopauza / 
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Experimental groups
•	 Tamoxifen experiments:	10	control	(10%	DMSO)	and	10	
tamoxifen	injections	for	each	Porsolt	FST	and	locomotor	
activity	experiment.
•	 Hormone replacement experiments:	
–	 Control	group	(n=10),
–	 Ovariectomy	and	sesame	oil	injections	(n=10),
–	 Ovariectomy	and	continuous	combined	estrogen	and	
progesterone	injections	(n=10),
–	 Ovariectomy	 and	 intermittent	 (sequential)	 estrogen	
and	progesterone	injections	(n=10).
Porsolt FST.	This	procedure	consists	of	exposing	an	animal	
to	a	situation	of	inescapable	stress,	in	which	the	rat	is	forced	to	
swim.	The	 rats	were	 placed	 individually	 in	 a	 cylinder	 (height,	
50	 cm;	 diameter,	 30	 cm);	 the	 level	 of	water	 did	 not	 allow	 the	
animal	to	lean	on	the	floor	or	arise	by	the	border.	The	temperature	
of	the	water	was	maintained	at	25ºC.	Animals	were	subjected	to	
two	trials	during	which	they	were	forced	to	swim	in	a	plexiglass	
cylinder	filled	with	water	and	from	which	they	could	not	escape.	
The	first	trial	lasted	15	minutes.	After	15	minutes	of	forced	swim	
each	animal	was	dried	with	paper	towels,	then	returned	to	their	
cages.	After	24	hours,	a	second	 trial	was	performed	 that	 lasted	
6	minutes.	The	first	1-minute	scores	were	excluded	to	allow	the	
rats	adaptation	period	to	the	experiments.	During	tests,	the	total	
freeze,	swim	duration,	and	struggling	were	measured.	Videotapes	
of	the	test	sessions	were	scored	by	an	experimenter	blind	to	the	
treatment	for	complete	immobility	time	(freeze	duration),	swim	
duration,	and	vigorous	struggle	time.	
Struggle	was	defined	as	follows:	attempts	to	jump	out	of	the	
tank;	attempts	to	climb	the	walls;	and	attempts	to	dive	into	the	
tank.	A	rat	was	considered	to	be	immobile	when	the	rat	floated	
or	made	only	small	movements	necessary	to	keep	the	nose	above	
the	water.		Statistical	analysis	was	performed	for	the	first	5	(6-1)	
minutes	on	days	1	and	2.	The	results	of	the	1st	day	15	minutes	
were	analyzed	separately.		
Locomotor activity experiments.	 The	 locomotor	 activity	
of	 each	 group	 of	 animals	 was	 tested	 in	 30x30x30	 transparent	
plexiglass	 cages.	 The	 cages	 were	 comprised	 of	 infrared	 light	
sources,	 photocells,	 and	 a	 computer	 unit.	 Locomotor	 activity	
cages	were	placed	in	a	silent	room	and	a	constant	tone	of	sound	
was	given	to	mask	the	background	noise.	The	cross-over	of	the	
animal	and	block	of	infrared	source	through	the	different	corners	
of	the	cage	were	regarded	as	cross-over	movements	and	blocking	
the	 same	 light	 source	more	 than	once	 by	moving	on	 the	 same	
side	of	 the	cage	as	repeated	movements.	Repeated	movements,	
such	 as	 rearing,	 grooming,	 and	 extremity	movements,	 indicate	
stereotypical	 behavior.	The	 locomotor	 activities	 of	 the	 animals	
were	recorded	1	day	before	and	after	the	Porsolt	FST	for	a	time	
period	of	30	minutes.				
Statistics.	The	data	were	analyzed	using	SPSS	(version	8.0)	
to	perform	one-way	analysis	of	variance	(ANOVA)	with	multiple	
comparison	 test	of	Bonferroni.	Differences	between	 the	groups	
were	evaluated	by	the	post hoc	Duncan	test.	Effects	with	degrees	
of	 freedom	 (df)	 values	 exceeding	 unity	 in	 the	 numerator	were	
set	 to	 unity	 in	 a	 conservative	 Geisser-Greenhouse	 correction	
procedure;	the	level	of	rejecting	the	null	hypothesis	was	0.05.
Result
Porsolt FST.	 In	 hormone	 replacement	 experiments,	
treatment	 emerged	 as	 a	 significant	 factor	 [F(4,63)	 =	 3.207,	
p=0.018].	One-way	analysis	of	variance	revealed	that	the	groups	
were	different	on	the	2nd	day	[F(4,63)	=	2.678,	p	=	0.040]	and	
the	post hoc	 test	of	Bonferroni	indicated	significant	differences	
between	the	ovariectomized	and	estrogen-treated	ovariectomized	
groups,	 suggesting	 estrogen	 replacement	 to	 be	 effective	 in	
reducing	freeze	duration.	In	swim	duration,	only	days	emerged	
as	a	significant	factor	[F(4,63)	=	5.487,	p	=	0.022],	but	no	other	
group	 differences	 were	 observed.	 In	 struggling	 duration,	 days	
emerged	as	a	significant	effect	[F(4,63)	=	28.140,	p	=	0.001]	since	
the	rats	struggled	less	during	the	2nd	day	of	testing	compared	to	
the	1st	day,	indicating	behavioral	despair.
Figure 1. Freeze duration results of the Porsolt Forced Swim Test  
Cont: Intact control animals TAM: Tamoxifen OVX-V: Ovariectomy and vehicle, 
OVX-E: Ovariectomy and estrogen, OVX-EP: Ovariectomy and combined 
estrogen and progesterone, OVX-EintP: Ovariectomy and intermittent (sequential) 
progesterone. Different from OVX-V or Control  (Day 2): *p<0.05
Figure 2. Struggle duration results of the Porsolt Forced Swim Test  
Cont: Intact control animals TAM: Tamoxifen OVX-V: Ovariectomy and vehicle, 
OVX-E: Ovariectomy and estrogen, OVX-EP: Ovariectomy and combined 
estrogen and progesterone, OVX-EintP: Ovariectomy and intermittent (sequential) 
progesterone. Different from OVX-V (Day 2): *p<0.05. Different from control (Day 1): 
†p<0.05.
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In	 the	 tamoxifen	 experiments,	 days	 also	 emerged	 as	
a	significant	factor	[F(1,26)	=	5.165,	p	=	0.032].	An	interaction	
between	treatment	and	days	did	not	reach	statistical	significance,	
but	indicated	a	trend	in	this	direction	[F(1,26)	=	3.557,	p	=	0.071]	
as	 the	 increase	 in	 the	 freeze	duration	was	much	higher	on	day	
2	compared	to	intact	rats.	Along	the	same	lines,	on	the	2nd	day	
there	 was	 a	 trend	 in	 the	 tamoxifen-treated	 group	 for	 a	 higher	
freeze	 duration	 compared	 to	 intact	 rats,	 although	 the	 level	 of	
significance	was	<	0.05	(p=0.068).	In	swim	duration,	no	significant	
differences	were	observed.	In	struggling	duration,	days	emerged	
as	a	significant	effect	[F(1,26)	=	40.554,	p	=	0.001]	because	the	
rats	struggled	less	during	the	2nd	day	of	testing	compared	to	the	
1st	day,	indicating	behavioral	despair	(Figures	1	and	2).
Locomotor activity experiments.	 The	 number	 of	 repeated	
movements	significantly	decreased	after	the	Porsolt	FST	(F(1,44)	
=	 8.483,	 P<0.006)	 in	 the	 hormone	 replacement	 experiments.	
Hormone	replacement	also	emerged	as	a	significant	factor	(F(1,44)	
=	 18.567,	 P<0.001).	 	 The	 sequential	 estrogen-progesterone	
replacement	group	had	a	significantly	higher	number	of	repeated	
movements	and	combined	the	estrogen-progesterone	replacement	
group	had	a	significantly	lower	number	of	repeated	movements	
(p<0.05).	
The	number	of	cage	crosses	significantly	decreased	after	the	
Porsolt	FST	(F(1,44)	=	31,116,	P<0.001).	Hormone	replacement	
also	emerged	as	a	significant	factor	(F(1,44)	=	17.868,	P<0.001).	
The	 combined	 estrogen-progesterone	 replacement	 group	 had	
a	 significantly	 lower	 number	 of	 repeated	 movements	 than	 the	
vehicle	and	estrogen-treated	ovariectomized	groups	(p<0.05).		
In	 the	 tamoxifen	 experiments,	 the	 number	 of	 repeated	
movements	significantly	decreased	after	the	Porsolt	FST	(F(1,26)	
=	 74.410,	 P<0.001).	 Tamoxifen	 treatment	 also	 emerged	 as	
a	 significant	 factor	 (F(1,26)	=	5.969,	P<0.022).	 	On	day	1,	 the	
tamoxifen-treated	group	had	a	higher	score	than	the	control	one	
based	on	the	Student’s	t-test	(p	=	0,013)
In	 the	 tamoxifen	 experiments,	 the	number	of	 cage	 crosses	
significantly	decreased	after	the	Porsolt	FST	(F(1,26)	=	70.304,	
P<0.001).	Tamoxifen	 treatment	had	no	significant	effect	on	 the	
number	of	cage	crosses.	
Discussion
The	 Porsolt	 FST	 is	 an	 animal	model	 of	 depression	 and	 is	
used	to	evaluate	new	anti-depressive	drugs	and	chemical	changes	
in	the	brain.	The	duration	of	immobility	indicates	the	degree	of	
depression	and	constitutes	one	of	the	important	parameters	of	the	
experiment.	The	increase	in	the	duration	of	immobility	on	day	2	
was	an	anticipated	finding.	Ovariectomized	rats	without	hormone	
replacement	showed	significantly	higher	durations	of	immobility.	
However,	the	increase	in	struggle	time	showed	an	anti-depressive	
behavior	of	the	animal	and	was	expected	to	be	shorter	on	day	2	
of	the	experiment.	On	day	2	ovariectomized	rats	without	estrogen	
replacement	were	significantly	different	from	all	three	hormone	
replacement	 groups.	 Overall,	 the	 results	 suggest	 that	 estrogen	
prevents	behavioral	despair,	and	is	more	effective	when	applied	
alone,	rather	than	in	combination	with	progesterone.
Studies	in	the	literature	support	the	converse	effect	of	these	
two	hormones	on	the	mood.	While	estrogen	has	been	shown	to	
increase	frontal	cerebral	blood	flow,	increase	degradation	of	the	
catabolic	 serotonin	enzyme	MAO,	affect	 the	 regulation	of	 free	
tryptophan	available	in	the	brain,	increase	density	of	5HT	binding	
sites	in	areas	that	control	mood	and	cognition,	progesterone	has	
been	shown	to	decrease	MAO	and	COMT	enzyme	activity,	act	as	
an	anti-estrogen,	and	down-regulate	estrogen	receptors	[16,	17].	
The	 overall	 outcome	 appears	 to	 be	 dose-dependent,	 and	while	
synthetic	progestin	 in	 estrogen-primed	postmenopausal	women	
washes	out	the	benefit	of	estrogen,	a	larger	dose	of	estrogen	can	
have	a	protective	effect.
In	a	meta-analysis	of	26	studies,	Zweifel	and	O’Brien	[18]	
evaluated	 the	 effects	 of	 hormones	 on	 mood	 in	 peri-and	 post-
menopausal	women;	overall	effect	sizes	of	0.68	for	estrogen	and	
progesterone	 and	0.69	 for	 unopposed	 estrogen	 are	 shown.	The	
effect	 size	was	 larger	 among	perimenopausal	women	 (1.81	vs.	
0.90,	respectively)	and	more	robust	if	the	duration	of	treatment	
was	>8	months.	
Although	 there	are	many	studies	about	HRT	on	mood	and	
behavior,	 there	 is	 limited	 data	 about	 SERMs	 on	 this	 issue.	 In	
a	prospective	clinical	trial	of	257	women	with	breast	cancer,	15%	
of	women	 treated	with	 tamoxifen	had	symptoms	of	depression	
compared	with	3%	in	controls,	6-12	months	following	treatment	
[14].	In	a	more	recent	multicenter	study	of	11,064	women	treated	
for	 5	 years,	 no	 difference	 existed	 between	 the	 tamoxifen	 and	
placebo	groups	with	respect	to	depression	and	overall	quality	of	
life	 [19].	 In	 a	 recent	 study	 of	 our	 laboratories	we	 investigated	
the	 effects	 of	 raloxifene	 on	 cognition	 and	 depression	 in	 rat	
experimental	 models.	 Raloxifene	 decreased	 immobilization	
(p<0.001)	 and	 increased	 struggling	 (p<0.001)	 in	 the	 Porsolt	
FST	 suggesting	 the	 prevention	 of	 despair.	 Raloxifene,	 as	
a	 SERM,	 acts	 as	 an	 antidepressant	 in	 ovariectomized	 rats	 and	
has	a	positive	 impact	on	memory	despite	 the	negligible	effects	
on	spatial	 learning	[13].	In	 the	present	study,	 intact	rats	having	
tamoxifen	showed	a	significantly	higher	duration	of	immobility.	
These	results	suggest	a	trend	for	tamoxifen	treatment	to	augment	
behavioral	despair.	
Although	 the	number	of	 repeated	movements	 significantly	
decreased	after	the	Porsolt	FST	in	locomotor	activity	experiments,	
the	tamoxifen	group	had	a	significantly	higher	number	of	repeated	
movements.	 The	 sequential	 estrogen-progesterone	 replacement	
group	had	a	significantly	higher	number	of	repeated	movements	
and	the	combined	estrogen-progesterone	replacement	group	had	
a	significantly	lower	number	of	repeated	movements.	The	number	
of	 cage	 crosses	 significantly	 decreased	 after	 the	 Porsolt	 FST,	
with	the	tamoxifen	group	showing	a	significantly	higher	number	
of	 repeated	 movements.	 The	 combined	 estrogen-progesterone	
replacement	group	had	a	significantly	lower	number	of	repeated	
movements	than	the	vehicle	and	estrogen-treated	ovariectomized	
groups.	The	combined	and	sequential	hormone	replacements	had	
significantly	different	results	in	locomotor	activities.	This	may	be	
due	to	the	longer	duration	of	progesterone	use	which	antagonized	
estrogen	activity	in	the	combined	HRT	group.	
Conclusion
In	 conclusion,	 although	 evidence	 is	 accumulating,	 many	
questions	regarding	the	factors	 that	play	a	role	in	the	cognitive	
neuroprotection	afforded	by	HRT	and	tamoxifen	remain	without	
answers.	While	studies	suggest	that	HRT	is	neuroprotective,	the	
protective	effect	of		tamoxifen	is	a	matter	of	debate.	More	studies	
with	larger	patient	populations	are	needed	to	find	the	remaining	
answers.			
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•••••••••••••••••••••••••••••••••••••••••••••••••••••
14-16 czerwca 
Patologia ciąży.
Kierownik naukowy: prof. dr hab. Romuald Dębski
•••••••••••••••••••••••••••••••••••••••••••••••••••••
29 sierpnia – 1 września
USG w ginekologii i położnictwie dla zaawansowanych.
Kierownik naukowy: prof. dr hab. Romuald Dębski
•••••••••••••••••••••••••••••••••••••••••••••••••••••
16-21 września
USG w ginekologii i położnictwie dla początkujących.  
Teoria i praktyka. 
Kierownik naukowy: prof. dr hab. Romuald Dębski
•••••••••••••••••••••••••••••••••••••••••••••••••••••
27-29 września
Doppler w ginekologii i położnictwie. 
Kierownik naukowy: prof. dr hab. Mariusz Dubiel
•••••••••••••••••••••••••••••••••••••••••••••••••••••
4-6 października
Diagnostyka prenatalna z elementami echokardiografii płodu.
Kierownik naukowy: dr hab. Dariusz Borowski
•••••••••••••••••••••••••••••••••••••••••••••••••••••
11-13 października
Kolposkopia dla zaawansowanych.
Kierownik naukowy: prof. dr hab. Andrzej Malarewicz
•••••••••••••••••••••••••••••••••••••••••••••••••••••
26-28.05.2011
Kolposkopia dla początkujących. 
Kierownik naukowy: prof. dr hab. Andrzej Malarewicz
•••••••••••••••••••••••••••••••••••••••••••••••••••••
21-24 listopada
USG w ginekologii i położnictwie dla zaawansowanych.
Kierownik naukowy: prof. dr hab. Romuald Dębski
•••••••••••••••••••••••••••••••••••••••••••••••••••••
––––––––––––––––––––––––––––––––––––––––––––––
Wsze lk ie  i n fo rmac je  o raz  zap isy  na  ku rsy :
www.usg.pisz.pl, usg@usg.pisz.pl
tel.: 0 504 075 804 (8:00-15:00)
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